Project Grant R01HL178954
Award Date
8/1/25
Completion Date
4/30/29
Dollars Obligated
$695K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,193,262 to The Regents of the University of California, San Francisco to develop an adeno-associated virus-mediated SGPL1 gene therapy as a potential first-in-class treatment for idiopathic pulmonary fibrosis (IPF). The research aims to confirm the efficacy of this gene therapy in reducing lung fibrosis and downstream profibrotic signaling in mouse models and...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $728,577 to investigate the role of purinergic signaling in idiopathic pulmonary fibrosis (IPF), a devastating lung disease. The research aims to elucidate how extracellular ATP and the fibroblast-specific ATP receptor P2RX4 regulate profibrotic pathways in lung fibroblasts, with the goal of validating P2RX4 as a novel therapeutic target for IPF. The 4-year...
This $1,546,880 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the regulatory mechanisms governing myofibroblast differentiation in idiopathic pulmonary fibrosis (IPF). The primary objectives are to: 1) determine the "regulatory architecture" of open chromatin in myofibroblasts in IPF, 2) examine how expression levels of E-box transcription factors...
This Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,410,668 to The Methodist Hospital Research Institute (HMRI) to investigate the role of cyclin-dependent kinase 9 (CDK9) in the pathogenesis and treatment of idiopathic pulmonary fibrosis (IPF). The research aims to elucidate the molecular mechanisms by which CDK9 regulates IPF, screen CDK9 inhibitors for anti-fibrotic efficacy, and develop an inhalable CDK9...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under CFDA 93.837 - Cardiovascular Diseases Research, provides $1,302,038 to the Regents of the University of Michigan to conduct research on targeting dysfunctional epithelial repair in pulmonary fibrosis. The research aims to elucidate the mediators and pathways that contribute to dysfunctional epithelial phenotypes in persistent lung fibrosis, determine the impact of hypoxia-inducible factor (HIF) signaling...
This federal Project Grant award of $683,564 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research focused on understanding the contribution of aberrant alveolar epithelial cells to the development and progression of pulmonary fibrosis. The 5-year award to The Trustees of the University of Pennsylvania, which began on Jul 1, 2025, will investigate how stress signaling through the PERK-ISR pathway impacts the emergence and...
This $110,959 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to understand the mechanisms driving the transition of lipofibroblasts to myofibroblasts in systemic sclerosis, a rare autoimmune fibrosing disease with high mortality. The research aims to define the role of the genes PER3 and CD36 in regulating the lipofibroblast to myofibroblast transition, which is a key driver...
This Project Grant award of $5,715,866 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop novel, transformative therapies that substantially reduce the burden of morbidity and mortality from progressive pulmonary fibrosis (PF). The multi-year program, which began in September 2024, focuses on investigating the transcriptomic, genetic, epigenetic, metabolic, and environmental signatures that contribute to the initiation and early...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $542,402 Project Grant under CFDA Program 93.837 - Cardiovascular Diseases Research to a research collaboration between Henry Ford Health and Michigan State University Health Sciences. The grant aims to screen novel compounds that can reverse profibrotic gene signatures associated with idiopathic pulmonary fibrosis (IPF), a fatal lung disease with limited treatment options. The project involves three key objectives: 1) in silico...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $299,295 to Fibrobiologics LLC to support the preclinical development of a novel therapeutic agent for the treatment of idiopathic pulmonary fibrosis (IPF). The funding, provided through the Cardiovascular Diseases Research program (CFDA 93.837), will enable Fibrobiologics to determine the antifibrotic activity of the peptide M10 in primary lung fibroblasts from IPF patients and evaluate its efficacy in two...